comparemela.com

Latest Breaking News On - Ezafungin - Page 1 : comparemela.com

Cidara Therapeutics Down 3% After Hours Following FDA Approval

By Josh Beckerman Cidara Therapeutics Inc. shares fell 3% to $1.84 in late trading after it said the Food and Drug Administration approved Rezzayo, or rezafungin for injection. The drug. | March 23, 2023

Josh beckermanDrug administrationCenters for diseaseMelinta therapeuticsCidara therapeutics incDisease controlDow jonesCidara therapeuticsNc stock exchangePress releaseHe cdtx us1717571079

Mundipharma: Napp announces acceptance of their Rezafungin Marketing Authorisation Application for the Treatment of Invasive Candidiasis to the UK Medicines and Healthcare Products Regulatory Agency

For UK Trade and Medical Media Only Rezafungin is a novel, once-weekly echinocandin being developed for both the treatment and prevention of serious fungal infections The Medicines and

United kingdomUnited statesGreat britainKostenloser wertpapierhandelBrian sheehanJan milton edwardsTara laniganAsia pacificCommunity registerEuropean commissionDrug administrationNapp pharmaceuticals limitedUs food drug administrationCidara therapeutics pressEuropean medicines agencyHealthcare products regulatory agency

Mundipharma and Cidara Therapeutics, Inc : Rezafungin Awarded Promising Innovation Medicine (PIM) Designation by the UK s Medicines and Healthcare Products Regulatory Agency (MHRA) for the Treatment of Invasive Candidiasis

For Trade and Medical Media Only Rezafungin is a next-generation once-weekly echinocandin being developed for both the treatment and prevention of serious fungal infections, such as invasive candidiasis

United statesSan diegoUnited kingdomTaylor sandisonPatrick burseyBrian sheehanJan milton edwardsAsia pacificBrian ritchieCommunity registerCidara therapeutics incEuropean commissionDrug administrationExchange commissionUs food drug administrationLifesci communications

Cidara Therapeutics and Mundipharma Announce Positive Topline Results from the Global Phase 3 Pivotal ReSTORE Trial of Rezafungin for the Treatment of Candidemia and Invasive Candidiasis

For Trade and Medical Media Only Trial met FDA and EMA-pre-specified primary endpoints versus daily standard of care Data to support global regulatory filings in mid-2022 Cidara to host investor

United statesSan diegoPatrick burseyBrian sheehanJan milton edwardsGeorge thompsonAsia pacificJeffrey steinBrian ritchieUniversity of californiaCommunity registerSchool of medicineCidara therapeutics incEuropean commissionDrug administrationExchange commission

vimarsana © 2020. All Rights Reserved.